Status:
COMPLETED
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Lead Sponsor:
Genentech, Inc.
Conditions:
Psoriasis
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who p...
Eligibility Criteria
Inclusion
- Signed informed consent
- Previous participation in Study ACD2600g
- For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study
Exclusion
- Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00096603
Start Date
October 1 2002
End Date
July 1 2004
Last Update
March 20 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.